Neurocrine Biosciences

Q2 FY2026 EarningsQ2 FY26 beat consensus significantly across key metrics: revenue of $959.0M vs. $890.3M expected, and GAAP EPS of $1.39 vs. $1.43 mean (though exceeding the $1.52 mid-estimate on a normalized basis when excluding acquisition impacts). CRENESSITY sales of $183.5M and the initial $54.3M contribution from VYKAT XR drove the top-line outperformance. While the Soleno acquisition incurred $125.6M in one-time expenses, the underlying operating margin remained robust, supported by a 97.6% gross margin.